ISTANBUL The rapid rise in the use of blockbuster weight-loss drugs such as Wegovy and Ozempic is straining US employers’ health budgets, prompting some to reconsider whether to cover the costly medications, according to a survey released this week by the nonprofit health research group KFF, CNN reported. Based in California, KFF, formerly the Kaiser Family Foundation, tracks US health policy trends and costs. Its latest survey found that 43% of large companies — those with more than 5,000